Santen Pharmaceutical Future Growth
Future criteria checks 2/6
Santen Pharmaceutical is forecast to grow earnings and revenue by 10.6% and 2.9% per annum respectively. EPS is expected to grow by 11.8% per annum. Return on equity is forecast to be 12.5% in 3 years.
Key information
10.6%
Earnings growth rate
11.77%
EPS growth rate
| Pharmaceuticals earnings growth | 9.9% |
| Revenue growth rate | 2.9% |
| Future return on equity | 12.50% |
| Analyst coverage | Good |
| Last updated | 16 Oct 2025 |
Recent future growth updates
Santen Pharmaceutical Co., Ltd. Just Missed EPS By 28%: Here's What Analysts Think Will Happen Next
Aug 09
Santen Pharmaceutical Co., Ltd. (TSE:4536) Just Released Its Annual Results And Analysts Are Updating Their Estimates
May 16Santen Pharmaceutical Co., Ltd. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
Feb 10Santen Pharmaceutical Co., Ltd. Just Beat EPS By 5.5%: Here's What Analysts Think Will Happen Next
Nov 11Santen Pharmaceutical Co., Ltd. Just Recorded A 25% EPS Beat: Here's What Analysts Are Forecasting Next
Aug 08Santen Pharmaceutical Co., Ltd. Just Missed Earnings - But Analysts Have Updated Their Models
May 11Recent updates
Santen Pharmaceutical (TSE:4536) Has Announced A Dividend Of ¥19.00
Sep 01Santen Pharmaceutical's (TSE:4536) Dividend Will Be ¥19.00
Aug 11Santen Pharmaceutical Co., Ltd. Just Missed EPS By 28%: Here's What Analysts Think Will Happen Next
Aug 09Santen Pharmaceutical (TSE:4536) Has Announced A Dividend Of ¥19.00
Jul 23Santen Pharmaceutical (TSE:4536) Is Due To Pay A Dividend Of ¥19.00
Jul 09Santen Pharmaceutical Co., Ltd. (TSE:4536) Just Released Its Annual Results And Analysts Are Updating Their Estimates
May 16Santen Pharmaceutical Co., Ltd. (TSE:4536) Not Lagging Market On Growth Or Pricing
Apr 19Santen Pharmaceutical's (TSE:4536) Dividend Will Be Increased To ¥19.00
Mar 06Santen Pharmaceutical Co., Ltd. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
Feb 10Santen Pharmaceutical (TSE:4536) Is Paying Out A Larger Dividend Than Last Year
Feb 09Santen Pharmaceutical (TSE:4536) Is Posting Promising Earnings But The Good News Doesn’t Stop There
Nov 18Santen Pharmaceutical Co., Ltd. Just Beat EPS By 5.5%: Here's What Analysts Think Will Happen Next
Nov 11Santen Pharmaceutical Co., Ltd.'s (TSE:4536) Share Price Could Signal Some Risk
Oct 14Calculating The Intrinsic Value Of Santen Pharmaceutical Co., Ltd. (TSE:4536)
Aug 31Santen Pharmaceutical Co., Ltd. Just Recorded A 25% EPS Beat: Here's What Analysts Are Forecasting Next
Aug 08Unpleasant Surprises Could Be In Store For Santen Pharmaceutical Co., Ltd.'s (TSE:4536) Shares
Jun 25Santen Pharmaceutical Co., Ltd. Just Missed Earnings - But Analysts Have Updated Their Models
May 11Is There An Opportunity With Santen Pharmaceutical Co., Ltd.'s (TSE:4536) 34% Undervaluation?
May 08Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 3/31/2028 | 313,979 | 40,938 | 39,099 | 54,100 | 8 |
| 3/31/2027 | 300,693 | 37,013 | 37,775 | 53,067 | 8 |
| 3/31/2026 | 292,743 | 33,189 | 43,541 | 54,587 | 9 |
| 6/30/2025 | 293,970 | 31,492 | 44,330 | 56,509 | N/A |
| 3/31/2025 | 300,004 | 36,247 | 49,909 | 60,928 | N/A |
| 12/31/2024 | 301,905 | 27,494 | 43,130 | 55,247 | N/A |
| 9/30/2024 | 302,563 | 26,124 | 63,311 | 73,225 | N/A |
| 6/30/2024 | 304,347 | 26,853 | 74,303 | 82,244 | N/A |
| 3/31/2024 | 301,965 | 26,634 | 62,758 | 72,649 | N/A |
| 12/31/2023 | 302,084 | 27,714 | 58,150 | 68,107 | N/A |
| 9/30/2023 | 295,928 | 26,364 | 33,466 | 46,547 | N/A |
| 6/30/2023 | 285,893 | -11,205 | 15,996 | 37,272 | N/A |
| 3/31/2023 | 279,037 | -14,955 | 12,559 | 37,147 | N/A |
| 12/31/2022 | 270,242 | -8,195 | 7,347 | 43,335 | N/A |
| 9/30/2022 | 266,413 | -9,133 | 17 | 37,279 | N/A |
| 6/30/2022 | 266,804 | 26,533 | 8,572 | 45,922 | N/A |
| 3/31/2022 | 266,257 | 27,212 | 10,202 | 46,043 | N/A |
| 12/31/2021 | 263,620 | 5,056 | 22,775 | 46,172 | N/A |
| 9/30/2021 | 259,459 | 7,319 | 22,195 | 47,476 | N/A |
| 6/30/2021 | 257,028 | 7,978 | 13,713 | 33,903 | N/A |
| 3/31/2021 | 249,605 | 6,826 | 15,004 | 38,808 | N/A |
| 12/31/2020 | 241,015 | 24,430 | 13,214 | 36,409 | N/A |
| 9/30/2020 | 241,685 | 24,279 | 16,958 | 34,787 | N/A |
| 6/30/2020 | 239,982 | 23,404 | 26,917 | 42,393 | N/A |
| 3/31/2020 | 241,555 | 23,616 | 30,719 | 39,947 | N/A |
| 12/31/2019 | 243,142 | 28,876 | 28,909 | 37,562 | N/A |
| 9/30/2019 | 238,457 | 30,721 | 30,088 | 39,233 | N/A |
| 6/30/2019 | 236,679 | 31,498 | 32,229 | 41,100 | N/A |
| 3/31/2019 | 234,026 | 31,953 | N/A | 32,894 | N/A |
| 12/31/2018 | 229,560 | 31,291 | N/A | 36,492 | N/A |
| 9/30/2018 | 228,512 | 34,370 | N/A | 38,360 | N/A |
| 6/30/2018 | 225,477 | 33,083 | N/A | 34,561 | N/A |
| 3/31/2018 | 224,942 | 35,247 | N/A | 42,843 | N/A |
| 12/31/2017 | 217,021 | 30,580 | N/A | 39,581 | N/A |
| 9/30/2017 | 212,041 | 25,717 | N/A | 37,624 | N/A |
| 6/30/2017 | 205,038 | 24,756 | N/A | 30,180 | N/A |
| 3/31/2017 | 199,096 | 23,061 | N/A | 10,843 | N/A |
| 12/31/2016 | 196,754 | 23,299 | N/A | 4,869 | N/A |
| 9/30/2016 | 195,247 | 22,317 | N/A | 5,091 | N/A |
| 6/30/2016 | 197,322 | 53,155 | N/A | 8,601 | N/A |
| 3/31/2016 | 195,291 | 53,373 | N/A | 22,525 | N/A |
| 12/31/2015 | 194,193 | 57,729 | N/A | 29,919 | N/A |
| 9/30/2015 | 187,779 | 58,590 | N/A | 34,513 | N/A |
| 6/30/2015 | 176,124 | 27,842 | N/A | 30,263 | N/A |
| 3/31/2015 | 161,831 | 24,032 | N/A | 25,386 | N/A |
| 12/31/2014 | 156,559 | 17,923 | N/A | 23,350 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 4536's forecast earnings growth (10.6% per year) is above the savings rate (0.5%).
Earnings vs Market: 4536's earnings (10.6% per year) are forecast to grow faster than the JP market (7.7% per year).
High Growth Earnings: 4536's earnings are forecast to grow, but not significantly.
Revenue vs Market: 4536's revenue (2.9% per year) is forecast to grow slower than the JP market (4.5% per year).
High Growth Revenue: 4536's revenue (2.9% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 4536's Return on Equity is forecast to be low in 3 years time (12.5%).
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/04 07:49 |
| End of Day Share Price | 2025/11/04 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Santen Pharmaceutical Co., Ltd. is covered by 19 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Atsushi Seki | Barclays |
| Koichi Mamegano | BofA Global Research |
| Hidemaru Yamaguchi | Citigroup Inc |